Sino Biopharmaceutical Limited
SBMFF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $8,787,389 | $8,787,389 | $6,495,878 | $6,495,878 |
| % Growth | 0% | 35.3% | 0% | – |
| Cost of Goods Sold | $1,540,542 | $1,540,542 | $1,245,719 | $1,245,719 |
| Gross Profit | $7,246,847 | $7,246,847 | $5,250,159 | $5,250,159 |
| % Margin | 82.5% | 82.5% | 80.8% | 80.8% |
| R&D Expenses | $1,593,779 | $1,593,779 | $1,255,431 | $1,255,431 |
| G&A Expenses | $546,765 | $546,765 | $515,162 | $515,162 |
| SG&A Expenses | $3,771,717 | $3,771,717 | $2,655,767 | $2,655,767 |
| Sales & Mktg Exp. | $3,224,952 | $3,224,952 | $2,140,606 | $2,140,606 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,365,496 | $5,365,496 | $3,911,198 | $3,911,198 |
| Operating Income | $1,881,352 | $1,881,352 | $1,193,262 | $1,193,262 |
| % Margin | 21.4% | 21.4% | 18.4% | 18.4% |
| Other Income/Exp. Net | $1,102,130 | $1,102,130 | -$361,536 | -$361,536 |
| Pre-Tax Income | $2,983,482 | $2,983,482 | $831,726 | $831,726 |
| Tax Expense | $490,662 | $490,662 | -$181,763 | -$181,763 |
| Net Income | $1,694,296 | $1,694,296 | $241,336 | $241,336 |
| % Margin | 19.3% | 19.3% | 3.7% | 3.7% |
| EPS | 0.094 | 0.094 | 0.014 | 0.014 |
| % Growth | 0% | 572.1% | 0% | – |
| EPS Diluted | 0.094 | 0.094 | 0.014 | 0.014 |
| Weighted Avg Shares Out | 18,024,420 | 18,024,420 | 17,244,444 | 17,244,444 |
| Weighted Avg Shares Out Dil | 18,025,875 | 18,025,875 | 18,180,281 | 18,180,281 |
| Supplemental Information | – | – | – | – |
| Interest Income | $928,033 | $928,033 | $448,918 | $448,918 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $264,949 | $264,949 | $234,963 | $240,598 |
| EBITDA | $1,969,192 | $1,969,192 | $1,084,489 | $1,090,124 |
| % Margin | 22.4% | 22.4% | 16.7% | 16.8% |